The global G-CSF and G-CSF Biosimilars market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The USA market for Global G-CSF and G-CSF Biosimilars market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The China market for Global G-CSF and G-CSF Biosimilars market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global G-CSF and G-CSF Biosimilars market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
G-CSF, which is also known as filgrastim, is a growth factor used to aid the recovery of bone marrow after chemotherapy treatment for cancer, especially in patients with neutropenia (low white blood cell count in the blood), which causes reduced resistance to infections. It can also be used to stimulate mobilization of haematopoietic stem cells for collection and transplantation.
This report aims to provide a comprehensive presentation of the global market for G-CSF and G-CSF Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding G-CSF and G-CSF Biosimilars. This report contains market size and forecasts of G-CSF and G-CSF Biosimilars in global, including the following market information:
- Global G-CSF and G-CSF Biosimilars Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global G-CSF and G-CSF Biosimilars Market Sales, 2018-2023, 2024-2030, (K Units)
- Global top five G-CSF and G-CSF Biosimilars companies in 2022 (%)
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Blood Disorders Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of G-CSF and G-CSF Biosimilars include Pfizer, Novartis, Roche, Merck & Co., Sanofi, Johnson & Johnson, Gilead Science, GlaxoSmithKline and AbbVie, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the G-CSF and G-CSF Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global G-CSF and G-CSF Biosimilars Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global G-CSF and G-CSF Biosimilars Market Segment Percentages, by Type, 2022 (%)
- Blood Disorders
- Oncology Diseases
- Chronic And Autoimmune Diseases
- Growth Hormone Deficiencies
Global G-CSF and G-CSF Biosimilars Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global G-CSF and G-CSF Biosimilars Market Segment Percentages, by Application, 2022 (%)
- Human Growth Hormone
- Erythropoietin
- Monoclonal Antibodies
- Insulin
- Interferon
Global G-CSF and G-CSF Biosimilars Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global G-CSF and G-CSF Biosimilars Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies G-CSF and G-CSF Biosimilars revenues in global market, 2018-2023 (Estimated), ($ millions)
- Key companies G-CSF and G-CSF Biosimilars revenues share in global market, 2022 (%)
- Key companies G-CSF and G-CSF Biosimilars sales in global market, 2018-2023 (Estimated), (K Units)
- Key companies G-CSF and G-CSF Biosimilars sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Pfizer
- Novartis
- Roche
- Merck & Co.
- Sanofi
- Johnson & Johnson
- Gilead Science
- GlaxoSmithKline
- AbbVie
- Amgen
- AstraZeneca
- Bayer
Outline of Major Chapters:
Chapter 1: Introduces the definition of G-CSF and G-CSF Biosimilars, market overview.
Chapter 2: Global G-CSF and G-CSF Biosimilars market size in revenue and volume.
Chapter 3: Detailed analysis of G-CSF and G-CSF Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of G-CSF and G-CSF Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global G-CSF and G-CSF Biosimilars capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
